President & CEO

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Institution	Shares	Value	Change
FMR	15,840,219	$593M	INCREASED
Vanguard	10,491,179	$393M	INCREASED
BlackRock	9,758,938	$365M	INCREASED
Farallon Capital Management	8,989,098	$336M	INCREASED
T. Rowe Price	8,222,969	$308M	INCREASED

Insider	Type	Shares	Value	Date
Richard Scott Struthers (President & CEO)	SELL	228,000	$9M	2026-09-01
Richard Scott Struthers (President & CEO)	SELL	313,000	$15M	2026-09-01
Richard Scott Struthers (President & CEO)	SELL	240,000	$10M	2026-09-01
Richard Scott Struthers (President & CEO)	SELL	287,700	$19M	2026-09-01
Richard Scott Struthers (President & CEO)	SELL	244,205	$16M	2026-09-01

Member	Type	Amount	Date
Gilbert Cisneros (Democrat)	SALE	$15,001 - $50,000	2026-07-30
Gilbert Cisneros (Democrat)	SALE	$15,001 - $50,000	2026-07-29

Crinetics Pharmaceuticals, Inc. (CRNX) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades